Data / Drug companies / Zydus Lifesciences Limited
Zydus Lifesciences Limited: 194 products in the FDA NDC directory, labeler code 65841
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Zydus Lifesciences Limited (labeler code 65841) lists 194 products in the FDA National Drug Code Directory, covering 43 finished drugs by generic name. By type: 132 prescription drugs, 62 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 16, 2026.
The request: Watch Zydus Lifesciences Limited (FDA labeler code 65841): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 65841
- Products in commercial distribution
- 194
- Packages
- 670
- Finished drugs by generic name
- 43
- Prescription products
- 132
- Over the counter products
- 0
- Flagged as original packager
- 132 of 132 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- September 28, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 132 | 68% |
| Bulk ingredients | 62 | 32% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 132 | 68% |
| Bulk ingredients | 62 | 32% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 61 | 31.4% |
| Tablet | 49 | 25.3% |
| Tablet, film coated | 41 | 21.1% |
| Capsule | 14 | 7.2% |
| Tablet, extended release | 7 | 3.6% |
| Capsule, delayed release | 6 | 3.1% |
| Capsule, coated pellets | 4 | 2.1% |
| Capsule, extended release | 3 | 1.5% |
| Tablet, film coated, extended release | 3 | 1.5% |
| Tablet, orally disintegrating | 2 | 1% |
| Tablet, chewable | 2 | 1% |
| Tablet, coated | 1 | 0.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Phthaloyl amlodipine | 65841-301 | Powder | Bulk ingredients | September 16, 2026 |
| Omeprazole | 65841-401 | Powder | Bulk ingredients | August 25, 2026 |
| Phenylbutazone | 65841-302 | Powder | Bulk ingredients | September 27, 2025 |
| Levofloxacin hemihydrate | 65841-011 | Powder | Bulk ingredients | March 7, 2025 |
| Mirabegron | 65841-192 | Powder | Bulk ingredients | January 2, 2025 |
| Ranolazine | 65841-191 | Powder | Bulk ingredients | January 2, 2025 |
| Roflumilast | 65841-190 | Powder | Bulk ingredients | January 2, 2025 |
| Entecavir | 65841-185 | Powder | Bulk ingredients | January 2, 2025 |
| Clindamycin | 65841-180 | Powder | Bulk ingredients | January 2, 2025 |
| Febuxostat | 65841-179 | Powder | Bulk ingredients | January 2, 2025 |
| Lurasidone | 65841-188 | Powder | Bulk ingredients | December 27, 2024 |
| Pitavastatin magnesium | 65841-183 | Powder | Bulk ingredients | December 27, 2024 |
| Rivastigmine | 65841-184 | Liquid | Bulk ingredients | December 24, 2024 |
| Tofacitinib citrate | 65841-194 | Powder | Bulk ingredients | December 21, 2024 |
| Teriflunomide | 65841-193 | Powder | Bulk ingredients | December 21, 2024 |
| Tizanidine hydrochloride | 65841-197 | Powder | Bulk ingredients | December 20, 2024 |
| Trazodone hydrochloride | 65841-196 | Powder | Bulk ingredients | December 20, 2024 |
| Azathioprine | 65841-195 | Powder | Bulk ingredients | December 20, 2024 |
| Duloxetine hydrochloride | 65841-189 | Powder | Bulk ingredients | December 20, 2024 |
| Fingolimod | 65841-187 | Powder | Bulk ingredients | December 20, 2024 |
| Mesalamine | 65841-186 | Powder | Bulk ingredients | December 20, 2024 |
| Esomeprazole magnesium dihydrate | 65841-182 | Powder | Bulk ingredients | December 20, 2024 |
| Silodosin | 65841-181 | Powder | Bulk ingredients | December 19, 2024 |
| Paroxetine hydrochloride hemihydrate | 65841-177 | Powder | Bulk ingredients | December 19, 2024 |
| Metoprolol succinate | 65841-144 | Powder | Bulk ingredients | December 19, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.